Palvella Therapeutics, a clinical-stage biopharmaceutical company focused on developing treatments for rare, serious skin diseases with no FDA-approved therapies, has announced a new product candidate, QTORIN™ pitavastatin, for treating disseminated superficial actinic porokeratosis (DSAP). The product was developed using Palvella's patented QTORIN™ platform, which creates novel, ... Https://www.coherentmarketinsights.com/news/palvella-unveils-qtorintm-pitavastatin-for-rare-skin-disease-1816